Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone for everolimus-induced oral stomatitis (MIST)
NCT03839940Phase 3Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone in stomatitis, sponsored by Cancer and Leukemia Group B. Primary endpoints: Incidence Rate of mTOR Inhibitor-associated Stomatitis-Related Pain at 8 weeks and Severity of Mouth Pain Scores at 8 weeks. Started Jun 2019; status: terminated.
02
Drugs
dexamethasone
03
Conditions
stomatitis
Beyond the preview
Go deeper on NCT03839940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839940.